BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
    • Interviews
  • News
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Exosomes
  • CAR-T
  • Cord Blood
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » iPS cells » Page 7

Harnessing iPS Cells for Drug Development and Discovery

August 15, 2017 By Cade Hildreth (CEO) Leave a Comment

iPS Cells for Drug Development & Discovery

Since the discovery of induced pluripotent stem cells (iPS cells) in 2006, a great deal of basic research has been done to understand how to produce, manipulate, and utilize the cell type. iPS cells are revolutionizing regenerative medicine, because they represent a potential route for producing patient-specific stem cells for research applications or clinical use. iPS cells also show great promise for phamaco-toxicological screening, by allowing disease modeling and safety assessment of potential new drugs.

iPS Cells in Drug Discovery and Disease Modeling

iPS Cells for Drug DiscoveryiPS cells have the potential to transform drug discovery by providing physiologically relevant human cells for compound identification, target validation, compound screening, and tool discovery. They can be used to produce a wide variety of mature human cell types, allowing potential drug compounds to be screened in high-throughput systems using human cells.

Additionally, iPS cells allow for the creation of patient specific cell populations, facilitating in vitro drug testing that replicates the disease conditions of the patient population of interest.  This approach facilitates early determination of whether a specific genetic population will respond well to a drug candidate, a process known as “personalized medicine.”

Currently, all but one of the clinical trials underway with iPS cells involve the creation and evaluation of iPS cell lines from specific patient population to determine whether the cell lines will be a good model for a disease of interest in a specific patient population. The only exception to this is Cynata’s clinical trial underway for GvHD in the UK that involves a MSC-derived iPS cell product. [Read more…]

Filed Under: iPS Cells Tagged With: drug discovery, iPS cells

Axiogenesis and Metrion Biosciences to Develop Human iPSC-derived Cardiomyocytes and Neurons

November 7, 2016 By Cade Hildreth (CEO) Leave a Comment

Axiogenesis AG

Axiogenesis announced today that it will be collaborating with Metrion Biosciences to validate, optimise and commercialise iPSC-derived cell based assays to facilitate drug discovery and more accurately predict cardiac arrhythmia and neuronal risk. Metrion Biosciences a UK-based contract research organization (CRO) that is best known as an ion channel specialist.

Metrion BiosciencesThrough this strategic partnership, Axiogenesis continues to strengthen its position within the iPS cell marketplace as a leading provider of cell-based solutions to facilitating drug discovery, safety, and toxicology applications. To learn more, see the full press release, included below with permission from Axiogenesis.

Axiogenesis is a fascinating company specializing in the development of induced pluripotent stem cells (iPSCs) and tissue types. It is the second largest iPSC company in the world after Cellular Dynamics International (CDI), in Madison, Wisconsin.

Axiogenesis was also the first European company to license and adopt Yamanaka’s iPSC technology in 2010. The company now specializes in human induced pluripotent stem cell (hiPSC) products, including in vitro models of healthy and diseased cell types and tissues.

Filed Under: iPS Cells, Press Releases, Stem Cell News Tagged With: Axiogenesis, cardiomyocytes, collaboration, iPS cells, Metrion Biosciences

[BREAKING] Hitachi and CiRA at Kyoto Univeristy to Create Healthy Volunteers’ iPS Cell Panel

September 7, 2015 By Cade Hildreth (CEO) Leave a Comment

Hitachi, Ltd. and the Center for iPS Cell Research & Application (CiRA) at Kyoto University Agree to Collaborate

Important news was announced today within the induced pluripotent stem cell (iPS cell) industry in a press release distributed by Hitachi, Ltd.  The press release announced that Hitachi, Ltd. and the Center for iPS Cell Research and Application at Kyoto University have reached an agreement to collaborate in building a “healthy volunteers’ iPS cell panel.”  [Read more…]

Filed Under: iPS Cells, Stem Cells Tagged With: CiRA, Hitachi Ltd, iPS cells, iPSC, market news, press release, stem cells

CDI, a FUJIFILM company, Announces Launch of World’s Largest Public Stem Cell Bank

September 1, 2015 By Cade Hildreth (CEO) Leave a Comment

CDI, a FUJIFILM company, announces launch of the world's largest public stem cell bank

Cellular Dynamics International Announces Launch of CIRM hPSC Repository and First 300 iPSC Lines

Cellular Dynamics International (CDI), a FUJIFILM company since March of 2015, announced news today that has reverberated throughout the stem cell community, suggesting hope and progress for the future of stem cell research.
Cellular Dynamics International, owned by parent company FUJIFILM HoldingsAs an indisputable leader in the the manufacture and production of iPS cell products, Cellular Dynamics was awarded a $16 million grant by the California Institute of Regenerative Medicine in March of 2013. In that landmark funding awarded, CIRM allocated $16 million for CDI to create 3 induced pluripotent stem cell (iPSC) lines from 3000 healthy and diseased donors. At the same time, CIRM awarded Coriell Institute approximately $10 million to structure and store the iPSC lines within a secure biobanking facility, of which CDI was to be a “primary subcontractor.” [Read more…]

Filed Under: iPS Cells, Stem Cells Tagged With: biobanking, Cellular Dynamics International, CIRM, induced pluripotent stem cells, iPS cells, iPSC, iPSC bank

Induced Pluripotent Stem Cell News Round-Up | July 2015

August 12, 2015 By Cade Hildreth (CEO) Leave a Comment

Induced pluripotent stem cells (iPSCs) represent a rapidly evolving area of stem cell science. Since the discovery of the cell type in 2006, there have been several important market events, including the first ever clinical trial in humans which launched in August of 2013 to evaluate the capacity of iPSC-derived cell sheets for their ability to restore vision in patients with wet-type macular degeneration. While this trial has since been paused due to safety concerns, it represents a major milestone in clinical progress with iPSCs.

In another recent event that reverberated throughout the stem cell research community, the Supreme Court rejected the right of the Wisconsin Alumni Research Foundation (WARF) to control patents related to iPSC derivation in a landmark patent decision issued February 2015.

Indeed, every month there are major events occurring in the iPSC sector that shift industry dynamics. Read on to get informed about the most important iPSC market events that occurred in July of 2015.  [Read more…]

Filed Under: iPS Cells, Stem Cells Tagged With: current events, induced pluripotent stem cell, industry news, iPS cells, iPSC, iPSC market, news round up

  • « Previous Page
  • 1
  • …
  • 5
  • 6
  • 7
  • 8
  • Next Page »

Nanocellect

Marathon Products

Kimera Society

Let’s Get Social

  • Facebook
  • Twitter
  • LinkedIn
  • Pinterest
  • Instagram

Cart

Top Rated Products

  • Job Posting on BioInformant <Job Posting on BioInformant.com - Your Perfect Hire Is In Our Audience $297
  • U.S. Cord Blood Banking Survey <Cord Blood Banking Survey of U.S. Parents [2017] $197
  • Exosome Companies 2020 <Global Database of Exosome Companies $149 $97
My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2022 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: [email protected] | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.